EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Retrospective Review on Safety and Efficacy of Combination Biologic Therapy for Psoriasis

Nicole Kah Mun Yoong iD, Xin Lin Wong, John Sullivan

Australasian Journal of Dermatology · 2025

DOI: 10.1111/ajd.14584 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Australasian Journal of Dermatology, 2025. Verfasst von Nicole Kah Mun Yoong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sinclair DIRECT (Dermatology, Investigational Research, Education & Clinical Trials), East Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Psoriasis, Hidradenitis Suppurativa, Dermatologic Agents, Biological Products. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is limited data on the use of dual or combination biologic therapy in dermatological patients, particularly in psoriasis or with other coexisting dermatological conditions. However, this may be necessary for a small proportion of patients.

Methods

We conducted a retrospective review of 46 patients treated with dual or combination biologic therapy at a single dermatology practice in Sydney, Australia. The patient cohort consisted of 44 patients with psoriasis, 1 patient with hidradenitis suppurativa and 1 patient with a combination of hidradenitis suppurativa and psoriasis.

Results

Of 46 patients receiving a combination of biological agents, only 1 experienced an adverse effect that did not require cessation of therapy.

Conclusion

The use of combination biologic therapy may be an option for psoriasis patients with recalcitrant disease, in particular for those with concomitant psoriatic arthritis or other dermatological conditions. However, further studies are warranted to evaluate the efficacy, safety and health economics of this treatment approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisHidradenitis SuppurativaDermatologic AgentsBiological ProductsHumansRetrospective StudiesMaleFemaleAdultMiddle AgedDrug Therapy, CombinationAdalimumabInfliximabAgedEtanerceptAntibodies, Monoclonal, HumanizedUstekinumabBiological TherapyTreatment Outcome

Substanzen

AdalimumabInfliximabEtanerceptDermatologic AgentsAntibodies, Monoclonal, HumanizedUstekinumabBiological Products

Autor:innen und Institutionen

  • Sinclair DIRECT (Dermatology, Investigational Research, Education & Clinical Trials), East Melbourne, Victoria, Australia.
  • Monash Health, Clayton, Victoria, Australia.
  • School of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Department of Dermatology, Sutherland Hospital, Caringbah, New South Wales, Australia.
  • Kingsway Dermatology & Aesthetics, Miranda, New South Wales, Australia.

ORCID-Profile: Nicole Kah Mun Yoong

Zitieren

APA

Yoong, N. K. M., Wong, X. L., & Sullivan, J. (2025). Retrospective Review on Safety and Efficacy of Combination Biologic Therapy for Psoriasis. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14584

Vancouver

Yoong NKM, Wong XL, Sullivan J. Retrospective Review on Safety and Efficacy of Combination Biologic Therapy for Psoriasis. Australasian Journal of Dermatology. 2025. doi:10.1111/ajd.14584

BibTeX
@article{Yoong2025,
  author = {Yoong, Nicole Kah Mun and Wong, Xin Lin and Sullivan, John},
  title = {Retrospective Review on Safety and Efficacy of Combination Biologic Therapy for Psoriasis},
  journal = {Australasian Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ajd.14584}
}
Kostenlos starten →